June 21, 2018

Chasing the Next Biotech Unicorn

How private equity sets to thrive in the biotech boom in Hong Kong

New listing rules in Hong Kong for biotech and the healthcare reform in China are propelling capital raising activities in the region. Rocketed valuation in the biotech sector drives interest from private equity investments, who demand swift investment cycle with a clear profit-making path for going public. The importance of rigorous and timely pre-investment screening and due diligence process is at an all-time high.

Download this whitepaper to examine the potential opportunities and headwinds in the biotech state-of-play, as well as factors that would drive deal success.

Fill out the form to download this whitepaper.

Here are some other items you might be interested in:

The New State of M&A: Brazil

Download our new report about M&A in Brazil and get valuable insights into the present and future of due diligence, asset marketing and automation.

TTR Iberian Market - May 2021 Report

TTR's May M&A Report covering Portugal indicates a 10% decline in transaction volume compared to 2020 and EUR 3.71bn aggregate value. Read the report to find out more details about the state of M&A in Iberia.

Deal Drivers: AMERICAS Q1 2021

After a challenging year that saw deal activity freeze through H1 2020 as the outbreak of COVID-19 forced countries into lockdowns, the M&A market in the Americas has reset and recovered, posting steady deal numbers through Q1 2021. Aggregate deal value for the region reached US$658.73bn from 1,961 transactions announced in Q1 2021, up from US$236.77bn from 1,918 deals in the same period last year.